Figure 4
Antitumor effect of BA9 and BT942 in B-hIL2RA mice in MC38 tumor model for Early phase and Late phase treatment. (a) Early phase treatment: mean tumor volume of MC38 tumors in B-hIL2RA mice treated with vehicle versus anti-CD25 antibody (n = 8/group). Randomly, B-hIL2RA mice were grouped by weight and treated with anti-CD25 (10 mg/kg, i.p., twice a week). MC38 cells (5 × 105 cells) were injected s.c. into mice in the next day (day 0). (b) Late phase treatment: mean tumor volume of MC38 tumors in B-hIL2RA mice treated with vehicle versus anti-CD25 (n = 8). MC38 cells (5 × 105 cells) were injected subcutaneous into B-hIL2RA mice (day 0). Antibody treatments (10 mg/kg, i.p., twice a week) were started when tumors had grown to 50–60 mm3 (day 5). P values were calculated using two-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).
